Market Overview

UPDATE: Jefferies & Company Downgrades Nektar Therapeutics to Hold, Lowers PT

Share:
Related NKTR
Mid-Afternoon Market Update: CytomX Therapeutics Climbs Following Bristol-Myers Squibb Partnership; Medgenics Shares Slide
12 Biggest Mid-Day Gainers For Monday
4 Biotech Stocks to Watch (GuruFocus)

In a report published Monday, Jefferies & Company downgraded its rating on Nektar Therapeutics (NASDAQ: NKTR) from Buy to Hold, and lowered its price target from $10.00 to $8.00.

Jefferies noted, “We are downgrading NKTR to Hold from Buy with a new $8 PT based on increased regulatory risks in OIC. Recent FDA scrutiny on CV risks with chronic µ-opioid antagonist use translates to higher approval hurdles potentially involving add'l large CV outcome studies and potentially delaying naloxegol's approval/launch. Thus, NKTR is fairly valued on increased risks.”

Nektar Therapeutics closed on Friday at $8.15.

Latest Ratings for NKTR

DateFirmActionFromTo
Nov 2016Aegis CapitalInitiates Coverage OnBuy
Sep 2016Brean CapitalAssumesBuy
Jan 2016Janney CapitalInitiates Coverage onBuy

View More Analyst Ratings for NKTR
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Downgrades Analyst Ratings

 

Related Articles (NKTR)

View Comments and Join the Discussion!